Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank54
3Y CAGR-21.0%
5Y CAGR-22.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-21.0%/yr
vs -1.9%/yr prior
5Y CAGR
-22.2%/yr
Consistent
Acceleration
-19.1pp
Decelerating
Percentile
P54
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $173.24M | +17.5% |
| 2024 | $147.47M | -11.5% |
| 2023 | $166.73M | -52.5% |
| 2022 | $350.77M | -11.1% |
| 2021 | $394.66M | -35.1% |
| 2020 | $608.51M | +27.9% |
| 2019 | $475.95M | +25.8% |
| 2018 | $378.20M | +46.6% |
| 2017 | $257.90M | +86.9% |
| 2016 | $138.00M | - |